RA
XENT

Ramius Advisors’s Intersect ENT, Inc XENT Stock Holding History

Ramius Advisors’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-268,592
Closed -$7.33M – 353
2021
Q4 		$7.33M Buy
268,592
+172,623
+180% +$4.68M 2.57% 7
2021
Q3 		$2.61M Buy
+95,969
New +$2.37M 1.56% 16

Other funds holding XENT

VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ramius Advisors's XENT Position: Q1 2022 in Review

Ramius Advisors sold out of Intersect ENT, Inc (XENT) in Q1 2022, closing a stake of 268,592 shares — an estimated $7.33M sold.

Ramius Advisors first reported a position in XENT in Q3 2021 and held it in 2 quarters. The position peaked at $7.33M in Q4 2021. 131 funds tracked by Wall St. Rank hold XENT as of Q1 2022.

  • Ramius Advisors reported no remaining Intersect ENT, Inc position as of Q1 2022 after selling out during the quarter.
  • Ramius Advisors sold 268,592 Intersect ENT, Inc shares in Q1 2022, an estimated $7.33M.
  • Ramius Advisors first reported a position in Intersect ENT, Inc in Q3 2021 and held it in 2 quarters.
  • Ramius Advisors's Intersect ENT, Inc position peaked at $7.33M in Q4 2021.
  • 131 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q1 2022.

Based on Ramius Advisors's 13F filing for Q1 2022, filed 16 May 2022.